Forward P/S Multiple: RxSight (RXST)

The forward P/S ratio demonstrates a market overvaluation of RxSight, Inc. (RXST), whose dominance in the adjustable IOL segment is protected by patents. Meanwhile, the 1.80 value serves as the baseline indicator for price action. The stability of the R&D staff and active recruitment of sales agents are complemented by precision optics delivery logistics, ensuring the preservation of lens properties during transport.

rxsight.com - RXST Market Cap to Projected Revenue (period 07/04/2022 - 11/13/2026)

Summary analytical data breakdowns for RxSight Ophthalmic (RXST)

- market price and analyst price targets:

Price Chart RxSight|RXST - Consensus Target

- company stock exchange capitalization indicators:

Market Capitalization RxSight Ophthalmic|RXST - Total Enterprise Value

- issuer book value statistics:

Book Value per Share RxSight|RXST - Accounting Capitalization|Market Capitalization to Book Value Ratio rxsight.com|RXST - Company Total Asset Base

- debt and liquidity data:

- financial results and valuation multiples details:

RXST - Company Net Income|Expected Profit RxSight, Inc.|RXST - Market Cap to Net Income Ratio|Projected Price to Earnings RxSight Corp|RXST - PEG Multiple|EV/EBITDA Multiple RxSight Ophthalmic|RXST - Operating income before deduction of amortization|Earnings per share for the last twelve months RxSight|RXST - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months rxsight.com|RXST - Net earnings per share growth this year|Earnings growth forecast for next year RxSight, Inc.

- sales and revenue indicators:

RXST - Company Total Revenue|Company Projected Revenue RxSight|RXST - Market Cap to Revenue Ratio|Forward Price-to-Revenue Multiple RxSight Ophthalmic

Fundamental company analysis:RXST (RxSight)

The scale of the adoption of RxSight, Inc. (RXST) innovative light technologies in ophthalmic surgery correlates directly with the price action of the forward P/S chart. This metric reflects the market value of every dollar of expected revenue, allowing investors to assess the current balance of supply and demand through the ratio of market capitalization to projected sales, where an upward trend signals growing confidence in the future pace of business expansion.

Who RxSight, Inc. competes with

Price-to-Projected Revenue Ratio Boston Scientific Corporation BSX|EW - Forward Price-to-Revenue Multiple|ResMed Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio Insulet Inc.|ZBH: Forward P/S Multiple|Market Cap to Projected Revenue COO|ALGN (Align Technology) - Forward P/S Multiple|Globus Medical Inc (GMED) - Market Cap to Expected Sales Ratio|Forward P/S Multiple TMDX|Forward Price-to-Revenue Multiple Alphatec Corp ATEC|Forward P/S Multiple AORT (Artivion, Inc.)|Forward P/S Multiple enovis.com ENOV|IART - Price-to-Projected Revenue Ratio|ESTA: Price-to-Projected Revenue Ratio|BBNX (Beta Bionics Corp) - Forward Price-to-Revenue Multiple|IRADIMED Inc. - Forward Price to Sales|EMBC (Embecta Corp.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio tandemdiabetes.com TNDM|Price-to-Projected Revenue Ratio Axogen (AXGN)|SI-BONE Inc (SIBN) - Projected Price to Revenue|Orthofix International - Forward Price-to-Revenue Multiple|Forward P/S Multiple Bioventus Global BVS|OrthoPediatrics Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio treace.com TMCI|Strata Critical Medical (SRTA) - Price-to-Projected Revenue Ratio|Future Price to Revenue CARL (Carlsmed, Inc.)|Price-to-Projected Revenue Ratio ClearPoint Neuro Inc.|Forward Price-to-Revenue Multiple Stereotaxis Corporation (STXS)|Forward P/S Multiple STIM|SGHT - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Orchestra BioMed, Inc. OBIO|ANIK: Market Cap to Projected Revenue|NSPR: Forward Price-to-Revenue Multiple|Jin Medical International - Price to Expected Revenue Ratio|vivani.com (VANI) - Price-to-Projected Revenue Ratio|Xtant Medical - Forward Price to Sales|Forward Price-to-Revenue Multiple NMTC|Market Cap to Projected Revenue MODD (Modular Med)|Price-to-Projected Revenue Ratio Myomo, Inc (MYO)|Market Cap to Expected Sales Ratio Envoy Medical Inc|Forward P/S Multiple VVOS (Vivos Therapeutics)|Market Cap to Expected Sales Ratio envveno.com (NVNO)|SINTX Technologies - Forward P/S Multiple|Projected Price to Revenue Tenon Medical Inc. (TNON)|LFWD: Forward P/S Multiple|Autonomix Medical - Forward Price to Sales|Forward Price-to-Revenue Multiple IVF|BBLG (bonebiologics.com) - Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple AXNX (Axonics)|BIOL (BIOLASE Inc.) - Forward Price to Sales|Forward P/S Multiple DYNT (Dynatronics)|Market Cap to Expected Sales Ratio Paragon 28 Inc. (FNA)|INVO - Price-to-Projected Revenue Ratio